// Contents

Rapamycin, the dasatinib and quercetin combination, and NAD+ precursors are the three names that come up most in talk about “anti-aging pills”. All three have real science behind them, and in all three cases the science is more modest than the retellings suggest. Let us go stage by stage to see where the data ends.

How to read “extended lifespan”

Most of the strong results come from laboratory mice. The best test bed is the National Institute on Aging’s Interventions Testing Program (ITP): experiments run in parallel at several sites on genetically diverse animals, which reduces the chance of one-off results. In it, rapamycin extended mouse lifespan in both males and females.

Even so, it does not mean humans get the same effect. Mice have a different lifespan, metabolism and causes of death. Everything below should be read as “the hypothesis is being tested”, not “the compound works”.

Rapamycin (sirolimus)

Rapamycin blocks the mTOR signalling pathway, which links a cell’s nutrient supply to growth. It has long been used as an immunosuppressant after transplants, so its high-dose safety profile is well known: mouth ulcers, changes in lipids and glucose, and a higher risk of infection among the side effects.

For a healthy person the question is low, intermittent dosing. There are small safety and biomarker studies, but no large trials asking whether people stay healthy longer. Any off-label use is a decision for a physician, not an experiment from an internet protocol.

Senolytics

The idea: with age, “senescent” cells that have stopped dividing accumulate and release pro-inflammatory signals. If they are removed selectively, tissue might work better. In mice, clearing such cells improved several measures.

In people the data is early: small pilot studies of dasatinib plus quercetin in conditions where senescent cells are suspected to play a role, such as diabetic kidney disease and pulmonary fibrosis. These are safety and mechanism studies, not proof of benefit for a healthy person. Dasatinib is a cancer drug with serious side effects and does not exist as a supplement.

NAD+ precursors (NMN, nicotinamide riboside)

Levels of NAD+, a molecule involved in cellular energy metabolism, decline in tissues with age. In human studies, precursor supplements do raise NAD+ in blood. The open question is whether that changes muscle, vascular or metabolic function. Results so far are mixed and mostly come from small, short trials.

Product quality also needs checking. The supplement market is poorly standardized, and the legal status of NMN differs by country and has changed over time, so check the current rules with your national regulator.

What follows from this

  • Mouse data is a reason for trials, not for self-treatment.
  • If someone offers a rapamycin or senolytic “protocol” outside a clinic, ask about the indication, monitoring and who is responsible.
  • The only interventions with demonstrated effects on healthy life are physical activity, blood pressure and lipid control, not smoking and sleep. How to measure the result is a separate question, and there technology already helps.